Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Oncology ◽  
2014 ◽  
Vol 86 (2) ◽  
pp. 86-93 ◽  
Author(s):  
Jun Fukihara ◽  
Naohiro Watanabe ◽  
Hiroyuki Taniguchi ◽  
Yasuhiro Kondoh ◽  
Tomoki Kimura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Clinical Predictors ◽  
Predictors Of Response ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutant

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e19078-e19078
Author(s):  
Rosario Garcia Campelo ◽  
Teresa Moran ◽  
Felipe Cardenal ◽  
Guillermo Alonso-Jaudenes Curbera ◽  
Enric Carcereny Costa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Outcome ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Egfr Mutant ◽  
Nsclc Patients
Sign in / Sign up

Export Citation Format

Share Document